Nalmefene is under clinical development by Opiant Pharmaceuticals and currently in Pre-Registration for Acute Opioid Overdosage. According to GlobalData, Pre-Registration drugs for Acute Opioid Overdosage have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Nalmefene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nalmefene (OPNT-003) is under development for the treatment of opioid overdose. It is a long acting nasal spray, administered through intranasal route using intravail and nasal drug delivery technology. The drug candidate acts by targeting opioid receptors (delta,kappa and mu types).
Opiant Pharmaceuticals overview
Opiant Pharmaceuticals (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.
For a complete picture of Nalmefene’s drug-specific PTSR and LoA scores, buy the report here.